Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia.
Carla M MamoloVerna WelchRoland B WalterJoseph C CappelleriJames BrockbankMatthew CawsonChris KnightMichele WilsonPublished in: PharmacoEconomics (2020)
The introduction of GO for newly diagnosed and R/R AML would have a minimal impact on the budget of a US health plan and could result in cost savings in the combination therapy setting for newly diagnosed AML.